RepliCel Life Sciencesの収益
RepliCel Life Sciencesの収益は何ですか。
RepliCel Life Sciences, Inc.の収益は352.000kCAD$です。
収益の定義は何ですか。
収入とは、企業が通常の事業活動から得た収入であり、通常は商品やサービスの顧客への売却による収入です。
Revenue is also referred to as sales or turnover. Some companies receive revenue from interest, royalties, or other fees. Revenue may refer to business income in general, or it may refer to the amount, in a monetary unit, earned during a period of time, as in "Last year, Company X had revenue of $42 million". Profits or net income generally imply total revenue minus total expenses in a given period.
In accounting, revenue is often referred to as the "top line" due to its position on the income statement at the very top. This is to be contrasted with the "bottom line" which denotes net income.
TSXVのセクタHealth Careにおける収益の企業と比べるRepliCel Life Sciences
RepliCel Life Sciencesは何をしますか。
RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01, which has completed Phase I clinical trials for the treatment of chronic tendinosis; RCS-01 that is in Phase 2 clinical trials to treat aging and sun damaged skin; and RCH-01, which is in Phase 2 clinical trials for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.
RepliCel Life Sciencesと類似の収益
- Encounter Resourcesの収益は344.000kAUD$です。
- BPHの収益は344.000kAUD$です。
- Total Helium Ltdの収益は344.000kCAD$です。
- CYduct Diagnosticsの収益は344.783k$です。
- Glen Eagle Resourcesの収益は346.000kCAD$です。
- Televista SAの収益は350.000k€です。
- RepliCel Life Sciencesの収益は352.000kCAD$です。
- Bellevue Goldの収益は354.000kAUD$です。
- Bellevue Goldの収益は354.000kAUD$です。
- Synthesis Systemsの収益は355.000k$です。
- Vaccinex Incの収益は356.000k$です。
- Neuropathixの収益は359.457k$です。
- 473977の収益は360.000kAUD$です。